Partnering | M&A

Leveraging global industry relationships and deal experience
to support strategic transactions

Sell-Side Partnering

Securing non-dilutive capital and pharma partners' resources for clients

Business Development

Build the value story, construct high-impact marketing materials, identify optimal strategic partners, conduct outreach to global industry network, and facilitate due diligence and deal closing

Transaction Advisory

Create deal tension through a structured process, conduct asset valuation and deal comparables analyses to optimize financial terms, and leverage substantial LifeSci transaction experience to support negotiations

Buy-Side Partnering

Securing assets or companies to bolster clients' product portfolios

Search & Evaluation

Utilize client parameters of interest to identify opportunities, prioritize/tier identified opportunities, and leverage BD expertise and network to vet availability / transactability

Commercial Due Diligence

Evaluate the scientific, regulatory, and commercial merits of potential opportunities – backed by primary research (e.g., physicians, payers, patients) – and leverage LifeSci platform to understand investor sentiment on opportunities

Proven Success

We leverage LifeSci’s global industry relationships and decades of transaction experience to drive our clients’ business development initiatives

Transactions

Global industry network, including over 5,000 contacts

$ B
in total deal value

Experience across global markets (U.S., EU, Asia, LATAM, MENA)

Highlighted Deals

2022

Option to License
~$27M Equity Investment

2021

Exclusive License
$420M

2021

Exclusive China License
Undisclosed

2021

Exclusive License
Undisclosed

2019

Exclusive License
Undisclosed

2019

Exclusive License
$568M

2019

Option to License
$481M

2018

Acquisition
$420M

2018

Exclusive China License
$9.5M

2018

Product Acquisition
$30M

2016

Exclusive License
$469M

2016

Exclusive License
$230M

2016

Exclusive License
$100M

2015

Distribution Agreement
Undisclosed

2015

Product Acquisition
Undisclosed

2015

Exclusive License
$85M

2015

M&A
$30M

2014

Exclusive China License
$9M

2014

Exclusive License
Undisclosed

2013

Exclusive License
$121M

2012

Exclusive License
Undisclosed

2010

Exclusive License
$625M

2009

Exclusive License
$200M

2008

Exclusive License
$385M

Want to learn more?

We bring decades of experience to your challenges with a team that is uniquely designed to meet your needs.